The change in storage conditions, which are among the most important disadvantages of BioNTech vaccine, has been approved by the European Union (EU).
The European Drug Administration (EMA) has approved the vaccine to be temporarily stored at minus 25 to minus 15 degrees for up to two weeks. Until now, minus 90 to minus 60 degrees were allowed in special coolers for the storage of the vaccine. This situation was an obstacle to the distribution of the vaccine to poor countries.
EMA noted that the new storage conditions will facilitate the rapid distribution of the vaccine. Thus, the vaccine can be stored in standard medical refrigerators in pharmacy and doctor’s offices instead of special coolers.
UĞUR ŞAHİN: AN IMPORTANT STEP
Uğur Şahin, the founding partner of BioNTech, stated that the approval is an important step in the goal of delivering the vaccine to all people in the world, and that the vaccination practices coincide with the right timing in the process of moving from vaccination centers to local doctors and that it will accelerate the fight against the epidemic.
The company updated the information on storage conditions in a notification to the US Food and Drug Administration last month and stated that the vaccine can be stored for two weeks at minus 25 to minus 15 degrees.
DOSES FIRST COMES TO TURKEY
Turkey said Health Minister Fahrettin husband yesterday, Pfizer / biontech vaccine has been reported that reached Turkey the first dose prescribed for general use, a total of 1.4 million doses of vaccine storage conditions, where appropriate centers had recorded will be implemented starting next week.
PRODUCTION PERMIT IN THREE PLANTS FROM EMA
On the other hand, EMA gave vaccine production permission to Biontech’s new facility in Marburg, Germany. Until now, the active ingredient of the vaccine, mRNA, was produced at the factory in Marburg. According to BioNTech data, the facility in Marburg will become one of the largest vaccine production centers based on mRNA technology worldwide, following the permission from EMA. Up to one billion doses of vaccine can be produced annually at the facility when full capacity is put into production. Shipments of the first vaccines produced in Marburg are expected to begin in the second half of April.
In addition to EMA BioNTech’s facility in Marburg, it also gave production permission to the plant in Visp, Switzerland for the production of the Halix and Moderna vaccine in the Netherlands for the production of AstraZeneca vaccine.
SIDE EFFECT DISCUSSION BELOW